Cortechs.ai announced a strategic partnership with Siemens Healthineers to expand global access to its NeuroQuant neuroimaging technologies by integrating them into the Siemens Healthineers Digital Marketplace.
According to the company, the collaboration centers on integrating the FDA-cleared NeuroQuant Lesion Surveillance module into the Siemens imaging ecosystem. The technology provides automated lesion segmentation, volumetric quantification, and longitudinal tracking of lesion size and progression, enabling clinicians to access quantitative brain imaging data within existing radiology workflows.
The company claims these capabilities provide objective measurements to support evaluation of neurological disorders and help clinicians monitor disease progression and treatment response over time. The platform may also assist in detecting and tracking amyloid-related imaging abnormalities (ARIA) in patients receiving anti-amyloid therapies for Alzheimer’s disease.
By distributing NeuroQuant through Siemens Healthineers’ digital infrastructure, the companies aim to accelerate adoption of quantitative brain imaging worldwide, improve diagnostic precision, and streamline clinical workflows in neurology and dementia care.
Cortechs.ai develops AI-powered medical imaging software designed to quantify and monitor structural brain changes associated with neurological conditions, helping clinicians detect and track diseases such as Alzheimer’s, multiple sclerosis, and brain tumors.
